BrightPath Biotherapeutics Co., Ltd. (TSE: 4594)
Health Care · Biotechnology · JP
¥53.00
+1.92% today · -34.6% 1Y
BrightPath Biotherapeutics Co., Ltd. (TSE: 4594) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.30M and employs 42 people.
Over the last twelve months the share price has lost 34.6%, trading between 43.00 and 96.00.
Tweenvest scores BrightPath Biotherapeutics Co., Ltd. across four factors: quality 28/100. Its strongest factor is quality.
4594 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.30M
- Revenue (TTM)
- $528.00
- P/E
- —
- EPS
- -11.70
- Dividend yield
- —
- Beta (5Y)
- 1.30
- 52-week high
- ¥96.00
- 52-week low
- ¥43.00
- Avg volume (3M)
- —
- Shares outstanding
- 138.89M
- Employees
- 42
- Next earnings
- —
About BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
- ISIN
- JP3274140007
- Founded
- 2003
- Listed since
- Oct 22, 2015
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.18 | -0.13% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $444.98 | +0.26% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.96 | +0.15% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $549.00 | +0.26% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $834.94 | +0.78% |
| argenx SEENXTBR: ARGX | $63.06B | €872.80 | +1.00% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $140.88 | +1.43% |
Figures last refreshed Aug 18, 2026.